Will Equillium’s Itolizumab emerge the winner in the COVID-19 sweepstakes?
Equillium Bio (NASDAQ: EQ), a clinical–stage biopharmaceutical Company focused on bringing innovation in form of immune-modifying therapies to treat immuno-inflammatory diseases, announced the...
